Live Breaking News & Updates on என்கிறார் பாரத் பயோடெக்
Stay updated with breaking news from என்கிறார் பாரத் பயோடெக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bharat Biotech: World Health Organisation Nod For Covaxin COVID-19 Vaccine Emergency Use Listing At The Earliest ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.
India's first indigenous COVID-19 vaccine manufacturer Bharat Biotech on Saturday said that it will be carrying out clinical trials in the US to support the marketing application for Covaxin in the country. ....
Once the results of Covaxin's phase 3 trials are out in July, its manufacturers have scheduled a phase 4 trial to test the vaccines real-world effectiveness, Bharat Biotech said today. ....
Covaxin can generate antibodies that may persist for 6-12 months, Bharat Biotech said. (File) Hyderabad: Covaxin, a COVID-19 vaccine being developed by Bharat Biotech, showed long-term antibody and T-cell (immune) memory responses three months after the shot in phase 1 volunteers and tolerable safety outcomes in Phase 2 study, the company has said, suggesting the antibodies may persist for six to 12 months. In phase 2, it also showed enhanced humoral and cell- mediated immune responses and the results were found in the safety and immunogenicity clinical trial of the vaccine candidate. Memory T cells are antigen-specific T cells that remain over a long term after an infection has been eliminated. ....
Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech The phase III human clinical trials, which began mid-November, target 26,000 volunteers across India. Covaxin was developed with help from ICMR and the National Institute of Virology. New Delhi: India s first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of the inoculant, Covaxin, announced today. The trials in the first and second phases had led to promising results. The phase III human clinical trials, which began mid-November, target 26,000 volunteers across India. Covaxin was evaluated in approximately 1,000 subjects in the first two phases, with the results receiving acceptance in international peer-reviewed scientific journals, a statement from Bharat Biotech said today. ....